Orexigen Therapeutics posts $1.45 million operating loss for January

By Caroline Salls

Pittsburgh, March 4 – Orexigen Therapeutics, Inc. reported a $1.45 million loss from operations for January on zero net product sales, according to its monthly operating report filed Monday with the Securities and Exchange Commission.

In comparison, Orexigen posted a $175,000 loss from operations for December, also on zero net product sales.

The net loss for January was $3.65 million, declining from a $771,000 December net gain.

The company had $26.47 million in cash and cash equivalents as of Jan. 31, down slightly from $26.93 million at the end of December.

Orexigen is a San Diego-based biopharmaceutical company focused on the treatment of obesity. The company filed for bankruptcy on March 12, 2018 under Chapter 11 case number 18-10518.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.